XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Note 1 - Organization, Basis of Presentation, and Summary of Significant Accounting Policies
9 Months Ended
Feb. 25, 2018
Notes to Financial Statements  
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]
1.
Organization , Basis of Presentation
,
and Summary of Significant Accounting Policies
 
Organization
 
Landec Corporation and its subsidiaries (“
Landec” or the “Company”) design, develop, manufacture
, and sell differentiated products for food and biomaterials markets
, and license technology applications to partners. The Company has
two
proprietary polymer technology platforms:
1
) Intelimer® polymers, and
2
) hyaluronan (“HA”) biopolymers. The Company sells specialty packaged branded Eat Smart® and GreenLine® and private label fresh-cut vegetables and whole produce to retailers, club stores
, and foodservice operators, primarily in the United States, Canada
, and Asia through its Apio, Inc. (“Apio”) subsidiary
, and sells HA-based and non-HA biomaterials through its Lifecore Biomedical, Inc. (“Lifecore”) subsidiary. The Company’s HA biopolymers and non-HA materials are proprietary in that they are specially formulated for specific customers to meet strict regulatory requirements. Through its O Olive Oil and Vinegar (“O Olive”) division, which the Company acquired on
March 1, 2017,
the Company sells premier California specialty olive oils and wine vinegars under the O brand to natural food, conventional grocery and mass retail stores, primarily in the United States and Canada.
 
The Company
’s technologies, along with its customer relationships and tradenames , are the foundation and key differentiating advantages upon which Landec has built its business.
 
Basis
of Presentation
 
The accompanying unaudited consolidated financial statements of Landec have been prepared in accordance with
United States generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions for Form
10
-Q and Article
10
of Regulation S-
X.
In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position of the Company at
February 25, 2018
and the results of operations and cash flows for all periods presented. Although Landec believes that the disclosures in these financial statements are adequate to make the information presented
not
misleading, certain information normally included in financial statements and related footnotes prepared in accordance with GAAP have been condensed or omitted in accordance with the rules and regulations of the Securities and Exchange Commission. The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in Landec's Annual Report on Form
10
-K for the fiscal year ended
May 28, 2017
.
 
The results of operations for
the
nine
months ended
February 25, 2018
are
not
necessarily indicative of the results that
may
be expected for an entire fiscal year because there is some seasonality in Apio’s food business, particularly, Apio’s export business
, and the order patterns of Lifecore’s customers which
may
lead to significant fluctuations in Landec’s quarterly results of operations.
 
Basis of Consolidation
 
The consolidated financial statements are presented on the accrual basis of accounting in accordance with
GAAP and include the accounts of Landec Corporation and its subsidiaries, Apio and Lifecore. All intercompany transactions and balances have been eliminated.
 
Arrangements that are
not
controlled through voting or similar rights are reviewed under the guidance for variable interest entities (“
VIEs”). A company is required to consolidate the assets, liabilities
, and operations of a VIE if it is determined to be the primary beneficiary of the VIE.
 
An entity is a VIE and subject to consolidation, if by design: a) the total equity investment at risk is
not
sufficient to permit the entity to finance its activities without additional subordinated financial support provided by any party, including equity holders
, or b) as a group the holders of the equity investment at risk lack any
one
of the following
three
characteristics: (i) the power, through voting rights or similar rights to direct the activities of an entity that most significantly impact the entity’s economic performance, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity. The Company reviewed the consolidation guidance and concluded that its partnership interest in Apio Cooling, LP and its equity investment in the non-public company are
not
VIEs.
 
Use of Estimates
 
The preparation of financial statements in conformity with
GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies; sales returns and allowances; inventories; self-insurance liabilities; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived assets including intangible assets; the valuation of investments; and the valuation and recognition of stock-based compensation and contingent liabilities
.
 
These estimates involve the consideration of comple
x
factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results
may
differ from management’s estimates.
 
C
ash and Cash Equivalents
 
The Company records all highly liquid securities with
three
months or less from date of purchase to maturity as cash equivalents. Cash equivalents consist mainly of money market funds. The market value of cash equivalents approxi
mates their historical cost given their short-term nature.
 
Inventories
 
Inventories are stated at the lower of cost (
first
-in,
first
-out method) or net realizable value and consist of the following (in thousands):
 
   
February 25
, 2018
   
May 28, 2017
 
Raw materials
  $
13,512
    $
10,158
 
Work in progress
   
3,756
     
3,447
 
Finished goods
   
11,481
     
11,685
 
Total
  $
28,749
    $
25,290
 
 
If the cost of the inventories exceeds their net realizable value, provisions are recorded
currently to reduce them to net realizable value. The Company also records a provision for slow moving and obsolete inventories based on the estimate of demand for its products.
 
Related Party Transactions
 
The Company sells products to and earns license fees
from Windset Holdings
2010
Ltd. (“Windset”). During the
three
months ended
February 25, 2018
and
February 26, 2017,
the Company recognized revenues of
$104
,000
and
$72
,000,
respectively. During the
nine
months ended
February 25, 2018
and
February 26, 2017,
the Company recognized revenues of
$299
,000
and
$265
,000,
respectively. These amounts have been included in product sales in the accompanying Consolidated Statements of Comprehensive Income. The related receivable balances of
$144
,000
and
$388,000
are included in accounts receivable in the accompanying Consolidated Balance Sheets as of
February 25, 2018
and
May 28, 2017,
respectively.
 
All related party transactions are monitored quarterly by the
Company and approved by the Audit Committee of the Board of Directors.
 
Debt Issuance Costs
 
The Company records its line of credit debt issuance costs as an asset, and as
such,
$120,000
and
$3
08
,000
were recorded as prepaid expenses and other current assets
, and other assets, respectively, as of
February 25, 2018,
and
$120,000
and
$399,000,
respectively, as of
May 28, 2017.
The Company records its term debt issuance costs as a contra-liability, and as such,
$60,000
and
$155
,000
was recorded as current portion of long-term debt
, and long-term debt, net, respectively, as of
February 25, 2018
and
$60,000
and
$201,000,
respectively, as of
May 28, 2017
. See Note
7
– Debt of the Notes to Consolidated Financial Statements for further information.
 
Financial Instruments
 
The Company
’s financial instruments are primarily composed of commercial-term trade payables, grower advances, notes receivable
, and debt instruments. For short-term instruments, the historical carrying amount approximates the fair value of the instrument. The fair value of long-term debt approximates its carrying value
.
 
Cash Flow Hedges
 
The Company entered
into an interest rate swap agreement to manage interest rate risk. This derivative instrument
may
offset a portion of the changes in interest expense. The Company designates this derivative instrument as a cash flow hedge. The Company accounts for its derivative instrument as either an asset or a liability and carries it at fair value in Other assets or Other non-current liabilities. The accounting for changes in the fair value of the derivative instrument depends on the intended use of the derivative instrument and the resulting designation.
 
For derivative instruments that hedge the exposure to variability in expected future cash flows that are designated as cash flow hedges, the effective portion of the gain or loss on the derivative instrument is reported as a component
of Accumulated Other Comprehensive Income in Stockholders’ Equity and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The ineffective portion of the gain or loss on the derivative instrument, if any, is recognized in earnings in the current period. To receive hedge accounting treatment, cash flow hedges must be highly effective in offsetting changes to expected future cash flows on hedged transactions.
 
Other Comprehensive Income
 
Comprehensive i
ncome consists of
two
components, net income and Other Comprehensive Income (“OCI”). OCI refers to revenue, expenses, and gains and losses that under GAAP are recorded as a component of stockholders’ equity but are excluded from net income. The Company’s OCI consists of net deferred gains on its interest rate swap derivative instrument accounted for as a cash flow hedge. The components of OCI and the changes in accumulated OCI, net of tax, are as follows (in thousands):
 
   
Unrealized Gains on
Cash Flow
Hedge
 
Accumulated OCI, net,
as of May 28, 2017
  $
432
 
Other comprehensive
income before reclassifications, net of tax effect
   
483
 
Amounts reclassified from OCI
   
 
Accumulated OCI, net,
as of February 25, 2018
  $
915
 
 
The Company does
not
expect any transactions or other events to occur that would result in the reclassification of any significant gains
or losses into earnings in the next
12
months.
 
Investment in Non-Public Company
 
On Februa
ry
15,
2011,
the Company made its initial investment in Windset which is reported as an investment in non-public company, fair value, in the accompanying Consolidated Balance Sheets as of
February 25, 2018
and
May 28, 2017.
The Company has elected to account for its investment in Windset under the fair value option. See Note
3
– Investment in Non-public Company for further information.
 
Intangible Assets
 
The Company
’s intangible assets are comprised of customer relationships with a finite estimated useful life of
eleven
to
thirteen
years
, and trademarks, tradenames and goodwill with indefinite useful lives.
 
Finite-lived intangible assets are reviewed for possible impairment whenever events or changes in circumstances occur that indicate that the carrying amount of an a
sset (or asset group)
may
not
be recoverable. Indefinite lived intangible assets are reviewed for impairment at least annually. For goodwill and other indefinite-lived intangible assets, the Company performs a qualitative impairment analysis in accordance with Accounting Standards Codification (“ASC”)
350
-
30
-
35.
 
Partial Self-Insurance on Employee Health and Workers Compensation Plans
 
The Company
 provides health insurance benefits to eligible employees under self-insured plans whereby the Company pays actual medical claims subject to certain stop loss limits and self-insures its workers compensation claims. The Company records self-insurance liabilities based on actual claims filed and an estimate of those claims incurred but
not
reported. Any projection of losses concerning the Company's liability is subject to a high degree of variability. Among the causes of this variability are unpredictable external factors such as inflation rates, changes in severity, benefit level changes, medical costs, and claims settlement patterns. This self-insurance liability is included in Other accrued liabilities in the accompanying Consolidated Balance Sheets and represents management's best estimate of the amounts that have
not
been paid as of
February 25, 2018
and
May 28, 2017.
It is reasonably possible that the expense the Company ultimately incurs could differ and adjustments to future reserves
may
be necessary.
 
Fair Value Measurements
 
The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has elected the fair value option for it
s investment in a non-public company. See Note
3
– Investment in Non-public Company for further information. The Company also measures its contingent consideration at fair value. See Note
2
– Acquisition of O Olive for further information. The Company has
not
elected the fair value option for any of its other eligible financial assets or liabilities.
 
The accounting guidance established a
three
-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:
 
Level
1
– observable inputs such as quoted prices for identical instruments in active markets.
 
Level
2
– inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.
 
Level
3
– unobservable inputs in which there is little or
no
market data, which would require the Company to develop its own assumptions.
 
As of
February 25, 2018
and
May 28, 2017,
the Company held certain assets that are required to be measured at fair value on a recurring basis, including its interest rate swap and its minority interest investment in Windset
.
 
The fair value of the Company
’s interest rate swap is determined based on model inputs that can be observed in a liquid market, including yield curves, and is categorized as a Level
2
measurement investment and is included in Other assets in the accompanying Consolidated Balance Sheets
.
 
The fair value of the Company
’s contingent consideration for the acquisition of O Olive utilizes significant unobservable inputs, including projected earnings before interest, taxes, depreciation and amortization (“EBITDA”) and discount rates. As a result, the Company’s contingent consideration associated with the O Olive acquisition is considered a Level
3
measurement liability. For the
nine
months ended
February 25, 2018,
the Company reduced its contingent consideration liability from
$5.9
million at
May 28, 2017
to
$5.4
million at
February 25, 2018
due to the change in projected EBITDA and discount rates during the
three
year earn out period ended
May 31, 2020.
 
The Company has elected the fair value option of accounting for its investment in Windset. The calculation of fair value utilizes significant unobservable inputs, including projected cash flows, gro
wth rates
, and discount rates. As a result, the Company’s investment in Windset is considered to be a Level
3
measurement investment. The change in the fair value of the Company’s investment in Windset for the
nine
months ended
February 25, 2018
was due to the Company’s
26.9%
minority interest in the change in the fair market value of Windset during the period. In determining the fair value of the investment in Windset, the Company utilizes the following significant unobservable inputs in the discounted cash flow models:
 
   
At
February 25, 2018
   
At
May 28, 2017
 
Revenue growth rates
 
 
6%
 
     
4%
 
Expense growth rates
 
 5%
to
6%
     
4%
 
Income tax rates
 
 
15%
 
     
15%
 
Discount rates
 
 
12%
 
     
12%
 
 
The revenue
growth, expense growth
, and income tax rate assumptions are considered the Company's best estimate of the trends in those items over the discount period. The discount rate assumption takes into account the risk-free rate of return, the market equity risk premium
, and the company’s specific risk premium and then applies an additional discount for lack of liquidity of the underlying securities. The discounted cash flow valuation model used by the Company has the following sensitivity to changes in inputs and assumptions (in thousands):
 
   
Impact on value of
investment in
Windset
as of
February 25, 2018
 
10% increase in revenue growth rates
  $
9,400
 
10% increase in expense growth rates
  $
(8,800
)
10% increase in income tax rates
  $
(500
)
10%
increase in discount rates
  $
(4,200
)
 
Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of
certain financial instruments could result in a different estimate of fair value at the reporting date.
 
The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring basis (in thousands):
 
   
Fair Value at
February 25, 2018
   
Fair Value at
May 28, 2017
 
Assets (liabilities):
 
Level 1
   
Level 2
   
Level 3
   
Level 1
   
Level 2
   
Level 3
 
Interest rate swap (1)
  $
    $
1,467
    $
    $
    $
688
    $
 
Investment in non-public company
   
     
     
65,800
     
     
     
63,600
 
Contingent consideration liability (2)    
     
     
(5,400
)    
     
     
(5,900
)
Total
  $
    $
1,467
    $
60,400
    $
    $
688
    $
57,700
 
 
 
(
1
)
Included
in Other assets in the accompanying consolidated balance sheets.
  (
2
)
Included in Other non-current liabilities in the accompanying consolidated balance sheets.
 
Revenue Recognition
 
See
Note
9
– Business Segment Reporting, for a discussion about the Company’s
four
business segments; namely, Packaged Fresh Vegetables, Food Export, Biomaterials, and Other
.
 
Revenue from product sales is recognized when there is persuasive evidence that an arrangement exists, title has transferred, the price is fixed and determinable, and collectability is reasonably assured. Allowances are established for estimated uncollect
ible amounts, product returns, and discounts based on specific identification and historical losses.
 
Apio
’s Packaged Fresh Vegetables revenues generally consist of revenues generated from the sale of specialty packaged fresh-cut and whole value-added vegetable products that are generally washed and packaged in Apio’s proprietary packaging and sold under Apio’s Eat Smart and GreenLine brands and various private labels. Revenue is generally recognized upon shipment of these products to customers. The Company takes title to all produce it trades and/or packages, and therefore, records revenues and cost of sales at gross amounts in the accompanying Consolidated Statements of Comprehensive Income.
 
In addition, Packaged Fresh Vegetables revenues include the re
venues generated from Apio Cooling, LP, a vegetable cooling operation in which Apio is the general partner with a
60%
ownership position, and from the sale of BreatheWay® packaging to license partners. Revenue is recognized on the vegetable cooling operations as cooling and storage services are provided to Apio’s customers. Sales of BreatheWay packaging are recognized when shipped to Apio’s customers.
 
Apio
’s Food Export revenues consist of revenues generated from the purchase and sale of primarily whole commodity fruit and vegetable products to Asia through its subsidiary, Cal-Ex Trading Company (“Cal-Ex”). As most Cal-Ex customers are in countries outside of the U.S., title transfers and revenue is generally recognized upon arrival of the shipment in the foreign port. Apio records revenue equal to the sale price to
third
parties because it takes title to the product while in transit. On February
28,
2018,
the Company announced its plans to discontinue Cal-Ex by May
27,
2018.
 
Lifecore
’s Biomaterials business principally generates revenue through the sale of products containing HA. Lifecore primarily sells products to customers in
three
medical areas: (
1
) Ophthalmic, which represented approximately
65%
of Lifecore’s revenues in fiscal year
2017,
(
2
) Orthopedic, which represented approximately
15%
of Lifecore’s revenues in fiscal year
2017,
and (
3
) Other/Non-HA products, which represented approximately
20%
of Lifecore’s revenues in fiscal year
2017.
The vast majority of Lifecore’s revenues are recognized upon shipment.
 
Lifecore
’s business development revenues, a portion of which are included in all
three
medical areas, are related to contract research and development (“R&D”) services and multiple element arrangement services with customers where the Company provides products and/or services in a bundled arrangement.
 
 
O Olive
’s business, which the Company acquired on
March 1, 2017,
sells premier California specialty olive oils and wine vinegars under the O brand to natural food, conventional grocery and mass retail stores, primarily in the United States and Canada. The revenues of O Olive are included in the Other segment. O Olive’s revenue is generally recognized upon shipment of its products to customers. The Company takes title to all products it trades and/or packages, and therefore, records revenues and cost of sales at gross amounts in the accompanying Consolidated Statements of Comprehensive Income.
 
Contract R&D revenue is recorded as earned, based on the performance requirements of the contract. Non-refundable contract fees for which
no
further performance obligations exist, and there i
s
no
continuing involvement by the Company, are recognized on the earlier of when the payment is received or collectability is reasonably assured.
 
For sales arrangements that contain multiple elements, the Company splits the arrangement into separate uni
ts of accounting if the individually delivered elements have value to the customer on a standalone basis. The Company also evaluates whether multiple transactions with the same customer or related party should be considered part of a multiple element arrangement, whereby the Company assesses, among other factors, whether the contracts or agreements are negotiated or executed within a short time frame of each other or if there are indicators that the contracts are negotiated in contemplation of each other. The Company then allocates revenue to each element based on a selling price hierarchy. The relative selling price for a deliverable is based on its vendor-specific objective evidence (“VSOE”), if available,
third
-party evidence (“TPE”), if VSOE is
not
available, or estimated selling price, if neither VSOE nor TPE is available. The Company then recognizes revenue on each deliverable in accordance with its policies for product and service revenue recognition. The Company is
not
typically able to determine VSOE or TPE, and; therefore, uses the estimated selling price to allocate revenue between the elements of an arrangement.
 
The Company limits the amount of revenue recognition for delivered elements to the amount that is
not
contingent on the future delivery
of products or services or future performance obligations or subject to customer-specific cancellation rights. The Company evaluates each deliverable in an arrangement to determine whether it represents a separate unit of accounting. A deliverable constitutes a separate unit of accounting when it has stand-alone value, and for an arrangement that includes a general right of return relative to the delivered products or services, delivery or performance of the undelivered product or service is considered probable and is substantially controlled by the Company. The Company considers a deliverable to have stand-alone value if the product or service is sold separately by the Company or another vendor or could be resold by the customer. Further, the revenue arrangements generally do
not
include a general right of return relative to delivered products. Where the aforementioned criteria for a separate unit of accounting are
not
met, the deliverable is combined with the undelivered element(s) and treated as a single unit of accounting for the purposes of allocation of the arrangement consideration and revenue recognition. The Company allocates the total arrangement consideration to each separable element of an arrangement based upon the relative selling price of each element. Allocation of the consideration is determined at arrangement inception on the basis of each unit’s relative selling price. In instances where the Company has
not
established fair value for any undelivered element, revenue for all elements is deferred until delivery of the final element is completed and all recognition criteria are met.
 
For licensing revenue, the initial license fees are deferred and amortized to revenue over the period of the agreement when a contract exists, the fee is fixed and
determinable, and collectability is reasonably assured. Noncancellable, nonrefundable license fees are recognized over the period of the agreement, including those governing R&D activities and any related supply agreement entered into concurrently with the license when the risk associated with commercialization of a product is non-substantive at the outset of the arrangement.
 
From time to time, the Company offers customers sales incentives, which include volume rebates and discounts. These amounts are est
imated on a quarterly basis and recorded as a reduction of revenue.
 
A summary of revenues by type of arrangement as described above is as follows (in thousands):
 
 
   
Three Months Ended
   
Nine
Months Ended
 
   
February 25,
2018
   
February
26,
2017
   
February 25,
2018
   
February 26,
2017
 
Recorded upon shipment
  $
141,575
    $
125,765
    $
373,486
    $
339,917
 
Recorded upon acceptance in foreign port
   
4,414
     
7,276
     
25,982
     
56,316
 
Revenue from multiple element arrangements
   
1,528
     
2,624
     
5,230
     
5,892
 
Revenue from license fees, R&D contracts and royalties/profit sharing
   
1,806
     
903
     
4,439
     
2,702
 
Total
  $
149,323
    $
136,568
    $
409,137
    $
404,827
 
 
Legal Contingencies
 
In the ordinary course of business, the Company is involved in various legal proceedings and claims.
 
The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least each fiscal quarter and adju
sted to reflect the impacts of negotiations, estimate settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.
 
Apio
has been the target of a union organizing campaign which has included
two
unsuccessful attempts to unionize Apio's Guadalupe, California processing plant. The campaign involved a union and over
100
former and current employees of Pacific Harvest, Inc. and Rancho Harvest, Inc. (collectively "Pacific Harvest"), Apio's labor contractors at its Guadalupe, California processing facility, bringing legal actions before various state and federal agencies, the California Superior Court, and initiating over
100
individual arbitrations against Apio and Pacific Harvest.
 
The
legal actions consisted of
three
main types of claims: (
1
) Unfair Labor Practice claims ("ULPs") before the National Labor Relations Board (“NLRB”), (
2
) discrimination/wrongful termination claims before state and federal agencies and in individual arbitrations, and (
3
) wage and hour claims as part of
two
Private Attorney General Act (“PAGA”) cases in state court and in over
100
individual arbitrations.
 
A settlement of the ULPs among the union, Apio, and Pacific Harvest that were pending before the NLRB was approved on
December 27, 2016
for
$310,000.
Apio was responsible for half of this settlement, or
$155,000.
On
May 5, 2017,
the parties to the remaining actions executed a
settlement agreement concerning the discrimination/wrongful termination claims and the wage and hour claims which covers all non-exempt employees of Pacific Harvest working at Apio's Guadalupe, California processing facility from
September 2011
through the settlement date. Under the settlement agreement, the plaintiffs are to be paid
$6.0
million in
three
installments:
$2.4
million, which was paid on
July 3, 2017,
$1.8
million which was paid on
November 22, 2017
and
$1.8
million which is due in
July 2018.
The Company and Pacific Harvest have each agreed to pay
one
half of the settlement payments. The Company paid the entire
first
two
installments of
$4.2
million and will be reimbursed by Pacific Harvest for its
$2.1
million portion which is included in Other assets in the accompanying Consolidated Balance Sheets. This receivable will be repaid through monthly payments until fully paid, which the Company expects to occur by
December 2020.
The Company and Pacific Harvest are each required to make
one
half of the
third
installment in
July 2018.
The Company’s recourse against non-payment by Pacific Harvest is its security interest in assets owned by Pacific Harvest.
 
As of
February 25, 2018
and
May 28, 2017,
the Company had accrued
$1
.0
million and
$3.2
million, respectively, related to these actions, which is included in Other accrued liabilities in the accompanying Consolidated Balance Sheets
.
 
Recent Accounting Guidance
Not
Yet Adopted
 
Revenue Recognition
 
In
May
 
2014,
the FASB issued ASU
2014
-
09,
which creates FASB ASC Topic
606
, Revenue from Contracts with Customers
and supersedes ASC Topic
605,
Revenue Recognition
(“ASU
2014
-
09”
). The guidance replaces industry-specific guidance and establishes a single
five
-step model to identify and recognize revenue. The core principle of the guidance is that an entity should recognize revenue upon transfer of control of promised goods or services to customers in an amount that reflects the consideration to which an entity expects to be entitled in exchange for those goods or services. Additionally, the guidance requires the entity to disclose further quantitative and qualitative information regarding the nature and amount of revenues arising from contracts with customers, as well as other information about the significant judgments and estimates used in recognizing revenues from contracts with customers. Since its original issuance, the FASB has issued several additional related ASUs to address implementation concerns and to further clarify certain guidance within ASU
2014
-
09.
The Company will adopt these updates beginning with the
first
quarter of its fiscal year
2019
and anticipates doing so using the modified retrospective method, which will be applied retrospectively only to the most current reporting period presented.
 
Currently, the Company is in the process of evaluating the impact of the adoption of ASU
2014
-
09.
As a result, the Company has initially identified the following core revenue streams from its contracts with customers:
 
 
Finished goods product sales (Packaged Fresh Vegetables
and O Olive);
 
Shipping and handling (Packaged Fresh Vegetables
and O Olive);
 
Product development and contract manufacturing arrangements (Biomaterials).
 
The Company
’s assessment efforts to date have included reviewing current accounting policies, processes, and systems requirements, as well assigning internal resources and
third
-party consultants to assist in the process. Additionally, the Company has reviewed historical contracts and other arrangements to identify potential differences that could arise from the adoption of ASU
2014
-
09.
Most notably, the Company is evaluating its current conclusions with respect to contract manufacturing arrangements for its Biomaterials business, as well as the timing of revenue recognition for its product development contract manufacturing arrangements in its Biomaterials business, to determine whether the application of ASU
2014
-
09
necessitates changes to such reporting. Beyond its core revenue streams, and the items listed above, the Company is also evaluating the impact of ASU
2014
-
09
on certain ancillary transactions and other arrangements.
 
Currently, the Company cannot reasonably estimate the impact the application of ASU
2014
-
09
will have upon its consolidate
d financial statements. The Company continues to assess the impact of ASU
2014
-
09,
along with industry trends and additional interpretive guidance, on its core revenue streams, and as a result of the continued assessment, the Company
may
modify its plan of adoption accordingly.
 
Leases
 
In
February 2016,
the FASB issued ASU
2016
-
02,
Leases (Topic
842
)
(“ASU
2016
-
02”
), which requires companies to generally recognize on the balance sheet operating and financing lease liabilities and corresponding right-of-use-assets. ASU
2016
-
02
also requires improved disclosures to help users of financial statements better understand the amount, timing and uncertainty of cash flows arising from leases. The Company will adopt ASU
2016
-
02
beginning in the
first
quarter of fiscal year
2020
on a modified retrospective basis
.
 
The Company is currently in the process of evaluating the impact that ASU
2016
-
02
will have upon its consolidated financial statements and related disclosures. The Company
’s assessment efforts to date have included:
 
 
Reviewing the provisions of ASU
2016
-
02;
 
Gathering information to evaluate its lease population and portfolio;
 
Evaluating the nature of its real and personal property and other arrangements that
may
meet the definition of a lease; and
 
Evaluating s
ystems’ readiness.
 
As a result of these efforts, the Company currently anticipates that the adoption of ASU
2016
-
02
will have a significant impact to its long-term assets and liabilities, as, at a minimum, virtually all of its leases designate
d as operating leases are expected to be reported on the consolidated balance sheets. The pattern of recognition for operating leases within the consolidated statements of comprehensive income is
not
anticipated to significantly change.
 
Income Taxes
 
In Fe
bruary
2018,
the FASB issued ASU
2018
-
02,
Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income
that permits a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act enacted in
December 2017.
The standard is effective for fiscal years beginning after
December 15, 2018.
Early adoption is permitted. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.